Anti-TNF artifacts

Johnson & Johnson's Centocor Inc. unit last week became the last company with a marketed anti-TNF alpha drug to add a label warning of an increased risk of hematologic events, perhaps because the rare events have been even more sparse among Remicade patients.

JNJ (New Brunswick, N.J.) issued a "Dear Healthcare Provider" letter and added the warning to Remicade's label, actions that it said were prompted by routine post-marketing surveillance. ...